Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick
Tag: Trappsol
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics announces positive safety profile of its drug Trappsol Cyclo
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer’s Disease
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Announces Partnership with United BioSource
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,